Patents by Inventor Andrea POLZER

Andrea POLZER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-IL12R?1 antibodies and their use in treating autoimmune and inflammatory disorders
    Patent number: 8999708
    Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: April 7, 2015
    Assignee: Novartis AG
    Inventors: Jose M. Carballido Herrera, Stefan Hartle, Christoph Heusser, Ingo Klagge, Andrea Polzer, Christoph Schwaerzler, Gabriela Wochnik-Veltrup
  • Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
    Patent number: 8945548
    Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: February 3, 2015
    Assignee: Novartis AG
    Inventors: Jose M. Carballido Herrera, Stefan Hartle, Christoph Heusser, Ingo Klagge, Andrea Polzer, Christoph Schwaerzler, Gabriela Wochnik-Veltrup
  • Anti-IL12Rbeta1 Antibodies And Their Use In Treating Autoimmune And Inflammatory Disorders
    Publication number: 20140120101
    Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
    Type: Application
    Filed: October 3, 2013
    Publication date: May 1, 2014
    Applicant: NOVARTIS AG
    Inventors: Jose M. CARBALLIDO HERRERA, Stefan HARTLE, Christoph HEUSSER, Ingo KLAGGE, Andrea POLZER, Christoph SCHWAERZLER, Gabriela WOCHNIK-VELTRUP
  • Anti-IL12Rbeta1 Antibodies And Their Use In Treating Autoimmune And Inflammatory Disorders
    Publication number: 20140099708
    Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
    Type: Application
    Filed: October 3, 2013
    Publication date: April 10, 2014
    Applicant: NOVARTIS AG
    Inventors: Jose M. CARBALLIDO HERRERA, Stefan HARTLE, Christoph HEUSSER, Ingo KLAGGE, Andrea POLZER, Christoph SCHWAERZLER, Gabriela WOCHNIK-VELTRUP
  • Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders
    Patent number: 8574573
    Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: November 5, 2013
    Assignee: Novartis AG
    Inventors: José M. Carballido Herrera, Stefan Hartle, Christoph Heusser, Ingo Klagge, Andrea Polzer, Christoph Schwaerzler, Gabriela Wochnik-Veltrup
  • ANTI-IL12RBETA1 ANTIBODIES AND THEIR USE IN TREATING AUTOIMMUNE AND INFLAMMATORY DISORDERS
    Publication number: 20120082681
    Abstract: The present invention relates to antibodies that specifically bind to IL12R?1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFN? production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN? production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.
    Type: Application
    Filed: October 4, 2011
    Publication date: April 5, 2012
    Applicant: NOVARTIS AG
    Inventors: José M. CARBALLIDO HERRERA, Stefan HARTLE, Christoph HEUSSER, Ingo KLAGGE, Andrea POLZER, Christoph SCHWAERZLER, Gabriela WOCHNIK-VELTRUP